Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons

The development of new devices and techniques has expanded the range of patients who benefit from endovascular treatment of femoropopliteal lesions. Paclitaxel-eluting devices have improved clinical results and treated-vessel patency at follow-up compared with conventional angioplasty. Currently, devices with different doses of paclitaxel are available in the market.

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

The COMPARE (Compare I Pilot Study for the Treatment of Subjects with Symptomatic Femoropopliteal Artery Disease) study compared low-dose (Ranger) vs. high-dose (IN-PACT) paclitaxel-coated balloons, showing that the former were non-inferior in terms of efficacy and safety after 1 year.

The aim of this prospective, multicenter study was to evaluate efficacy and safety results after 2 years.

The primary endpoint was absence of clinically guided treated-vessel revascularization or restenosis assessed by a Doppler study. Additionally, researchers analyzed a safety endpoint and clinical results.

This study analyzed 414 patients randomized between the low-dose arm and the high-dose arm. Mean patient age was 68 years old, and most subjects were male. The most frequent clinical presentation was Rutherford class III. There were no differences between groups in terms of the characteristics of treated lesions (lesion length, chronic occlusion %, and calcification level). Technical and procedural success rates were also similar.

Read also: Prognostic Impact of Acute Kidney Injury Following Tricuspid Transcatheter Edge-to-Edge Repair.

After 2 years, the patency rate was 70% for the low-dose arm, and 71% for the high-dose arm (p = 0.96). There was no difference in all-cause mortality or clinically guided revascularization.

Conclusion

This study has shown a sustained and comparable effect regarding the treatment of femoropopliteal lesions between balloons coated with low and high doses of paclitaxel in terms of treated-vessel patency and need for revascularization after 2 years.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions 2-Year Results From the COMPARE Trial.

Reference: Sabine Steiner, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...